• CPBM claims to have an improved formulation of ribavirin: in what sense, exactly, is it improved? Ribavirin has been extensively studied by Roche and Schering-Plough (now part of Merck); if there were a simple way to improve ribavirin’s efficacy or tolerability merely by varying the formulation, these companies would have done so years ago.
• The claims in CPBM’s recent PR with respect to the timing of product launches and product-revenue streams are preposterous, IMO.
• A common technique of scam biotech companies is to hype the ownership of a licensed patent that’s inconsequential from a business standpoint. This is what CPBM appears to be doing with the 6,387,662 patent.
• Despite spending a considerable amount of time and money, no one in the drug/biotech industry has been able to develop a vaccine for HCV or has even come close to having one. IMO, the notion that a tiny virtual company will succeed in such an endeavor is patently silly.
Market Data 
Markets 
AI
